Insite Clinical Research LLC

1. Indivior Inc. $5,413,642 288 payments
2. Vanda Pharmaceuticals Inc. $2,364,202 17 payments
3. Teva Pharmaceuticals USA, Inc. $2,101,536 162 payments
4. ITI, Inc. $1,532,148 55 payments
5. AbbVie, Inc. $777,201 21 payments
6. Otsuka Pharmaceutical Development & Commercialization, Inc. $513,807 10 payments
7. Eli Lilly and Company $479,356 8 payments
8. BioXcel Therapeutics, Inc. $389,099 10 payments
9. Sage Therapeutics, Inc. $369,993 39 payments
10. Alkermes, Inc. $315,886 25 payments

1. Evaluation of Efficacy and Safety of Iloperidone in the Treatment of Bipolar I Disorder $2,359,392 16 payments
2. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $2,101,536 162 payments
3. A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (Rbp-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-Risk Opioid Use $1,696,855 173 payments
4. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia $1,495,330 48 payments
5. A Single-Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of SUBLOCADE at Alternative Injection Locations in Adults $1,239,355 19 payments
6. An Open-Label, Multicentre Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Repeated Doses of Indv-6001 in Adults With Moderate to Severe Opioid Use Disorder $1,192,510 40 payments
7. A Phase I Double-Blind, Placebo-Controlled Randomized Study to Assess Repeated Doses of Indv-2000 (C4x_3256) Up to 28 Days in Healthy Volunteers, and An Open-Label Study of Indv-2000 Up to 11 Days in Treatment Seeking Individuals With Opioid Use Disorder $824,646 13 payments
8. Protocol 331-201-00081 A Multicenter, Randomized, Double-Blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With Or Without Mixed Features, Associated With Bipolar I Disorder $426,997 1 payment
9. A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $389,942 27 payments
10. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $384,943 6 payments

1. Patient care $45,077 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.